Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (241-250 of 280) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2018
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology GroupAndrea K Ng, Joachim Yahalom, Jayant S Goda, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood|February 7, 2001
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelC H Moskowitz, S D Nimer, A D Zelenetz, et al.
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Pageof 28

Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2018
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology GroupAndrea K Ng, Joachim Yahalom, Jayant S Goda, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood|February 7, 2001
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelC H Moskowitz, S D Nimer, A D Zelenetz, et al.
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Pageof 28